David P. Schenkein
valid: Two independent sources agree, or a primary source states it: the record asserts this claim, unless it is a post, is marked for review or carries a confidence below 0.5.asserted
- Valid from
- 2023-09-08
- Valid until
- still holds
- Published
- 2023-09-08
- Recorded by AsOf
- 2026-11-12
- Checked
- 2026-11-12 · its source page states the value and the date
- Confidence
- 0.95
Sources
“On September 8, 2023, Regeneron’s board of directors (the “ Board ”) elected Kathryn Guarini, Ph.D. as a Class III director and David P. Schenkein, M.D. as a Class II director to fill the two vacancies on the Board.”— what the page says, read 2026-11-12
Cite this claim
Plain text
AsOf. "Regeneron Pharmaceuticals board member: David P. Schenkein", as of 2023-09-08. Claim clm_CE05B7C86D54, https://asof.is/claim/clm_CE05B7C86D54, accessed 2026-11-13. Source: https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/0001104659-23-099345-index.htm.
APA
AsOf. (2023). Regeneron Pharmaceuticals board member: David P. Schenkein (as of 2023-09-08) [Record clm_CE05B7C86D54]. Retrieved November 13, 2026, from https://asof.is/claim/clm_CE05B7C86D54 (source: https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/0001104659-23-099345-index.htm)
BibTeX
@misc{asof_clm_CE05B7C86D54,
author = {AsOf},
title = {Regeneron Pharmaceuticals board member: David P. Schenkein},
year = {2023},
howpublished = {\url{https://asof.is/claim/clm_CE05B7C86D54}},
note = {Claim clm\_CE05B7C86D54, as of 2023-09-08; source: https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/0001104659-23-099345-index.htm},
urldate = {2026-11-13}
}On the record
/claim/clm_CE05B7C86D54.md/v1/claims/clm_CE05B7C86D54submit a correction